MA40721A - Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation - Google Patents

Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Info

Publication number
MA40721A
MA40721A MA040721A MA40721A MA40721A MA 40721 A MA40721 A MA 40721A MA 040721 A MA040721 A MA 040721A MA 40721 A MA40721 A MA 40721A MA 40721 A MA40721 A MA 40721A
Authority
MA
Morocco
Prior art keywords
interleukin
methods
fusion proteins
alpha receptor
receptor
Prior art date
Application number
MA040721A
Other languages
English (en)
Other versions
MA40721B1 (fr
Inventor
Thomas Malek
Original Assignee
The Univ Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40721(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Univ Of Miami filed Critical The Univ Of Miami
Publication of MA40721A publication Critical patent/MA40721A/fr
Publication of MA40721B1 publication Critical patent/MA40721B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
MA40721A 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation MA40721B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
EP15750560.3A EP3177307B1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
PCT/US2015/043792 WO2016022671A1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA40721A true MA40721A (fr) 2017-06-13
MA40721B1 MA40721B1 (fr) 2024-08-30

Family

ID=53836871

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40094A MA40094B1 (fr) 2014-08-06 2015-08-04 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA40721A MA40721B1 (fr) 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA40094A MA40094B1 (fr) 2014-08-06 2015-08-04 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Country Status (32)

Country Link
US (3) US12084483B2 (fr)
EP (2) EP3177307B1 (fr)
JP (3) JP6723982B2 (fr)
KR (1) KR102653758B1 (fr)
CN (2) CN107074967B (fr)
AU (3) AU2015301071C1 (fr)
BR (1) BR112017001940A2 (fr)
CA (1) CA2957273C (fr)
CL (1) CL2017000284A1 (fr)
CO (1) CO2017002166A2 (fr)
DK (1) DK3177307T3 (fr)
EA (2) EA202091342A3 (fr)
ES (1) ES2986097T3 (fr)
FI (1) FI3177307T3 (fr)
HR (1) HRP20241258T1 (fr)
HU (1) HUE068478T2 (fr)
IL (2) IL250007B (fr)
LT (1) LT3177307T (fr)
MA (2) MA40094B1 (fr)
MX (1) MX388977B (fr)
MY (1) MY180831A (fr)
PE (1) PE20170503A1 (fr)
PH (1) PH12017500042A1 (fr)
PT (1) PT3177307T (fr)
RS (1) RS65930B1 (fr)
SA (1) SA517380842B1 (fr)
SG (2) SG10201913695PA (fr)
SI (1) SI3177307T1 (fr)
SM (1) SMT202400414T1 (fr)
TN (1) TN2017000020A1 (fr)
WO (1) WO2016022671A1 (fr)
ZA (1) ZA201700245B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN111423513A (zh) 2014-02-06 2020-07-17 豪夫迈·罗氏有限公司 白介素-2融合蛋白和其用途
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (fr) * 2016-05-19 2021-12-29 The General Hospital Corporation Interleukine-2 liée à son récepteur il-2rbêta, plate-forme pour améliorer l'activité des cellules tueuses naturelles et des lymphocytes t régulateurs
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3596108A4 (fr) 2017-03-15 2020-12-23 Pandion Operations, Inc. Immunotolérance ciblée
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11780899B2 (en) 2017-12-06 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to IL-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US12280119B2 (en) 2018-03-23 2025-04-22 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
BR112020018709A2 (pt) * 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
CA3133414A1 (fr) * 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Variants du recepteur de l'interleukine-2 (il2r) et de l'interleukine-2 (il2) pour l'activation specifique de cellules effectrices immunitaires
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
KR20220012256A (ko) * 2019-05-24 2022-02-03 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
CN119591725A (zh) * 2019-07-12 2025-03-11 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
MX2022000991A (es) * 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
WO2021055568A1 (fr) * 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Compositions d'il-2 et leurs procédés d'utilisation
CA3157229A1 (fr) * 2019-10-18 2021-04-22 Alkermes Pharma Ireland Limited Agents il-2 immunolodulateurs en combinaison avec des inhibiteurs de point de controle immunitaire
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之ｉｌ２促效劑及其使用方法（二）
WO2021168079A1 (fr) 2020-02-21 2021-08-26 Pandion Operations, Inc. Immunotolérance ciblée sur un tissu avec un effecteur cd39
JP2023524077A (ja) 2020-04-30 2023-06-08 イテオ バイオセラピー，インク． 活性可能なｉｌ２の組成物および使用方法
WO2022036079A1 (fr) * 2020-08-13 2022-02-17 Bristol-Myers Squibb Company Procédés de redirection de l'il-2 vers des cellules cibles d'intérêt
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
KR20240149421A (ko) * 2022-02-11 2024-10-14 뮤럴 온콜로지, 인코포레이티드 암 면역요법을 위한 조성물 및 방법
US20250154216A1 (en) * 2022-02-16 2025-05-15 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
TW202434646A (zh) * 2023-02-22 2024-09-01 大陸商百奧賽圖(北京)醫藥科技股份有限公司 抗il2ra抗體及其用途
WO2025207491A1 (fr) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions et méthodes pour immunothérapie anticancéreuse

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US20040265272A1 (en) 2001-09-28 2004-12-30 Aikichi Iwamoto Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
WO2005091956A2 (fr) 2004-03-05 2005-10-06 Chiron Corporation Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients
EP3263581B2 (fr) 2005-05-17 2025-07-09 University of Connecticut Compositions et procédés d'immunomodulation dans un organisme
CN101255197B (zh) 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
US8734774B2 (en) * 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
WO2012088383A2 (fr) 2010-12-23 2012-06-28 Genentech, Inc. Interactions pilr alpha et procédés visant à les modifier
LT3401402T (lt) 2012-06-08 2020-12-28 Alkermes Pharma Ireland Limited Ligandai, modifikuoti cirkuliarinės permutacijos pagalba, kaip agonistai ir antagonistai
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (fr) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Amélioration de la demi-vie d'un polypeptide thérapeutique par fusion avec une protéine d'échafaudage trimère via un espaceur
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
HRP20241258T1 (hr) 2024-12-06
CO2017002166A2 (es) 2017-05-19
JP2023099045A (ja) 2023-07-11
EA201790063A1 (ru) 2017-06-30
EP4438621A3 (fr) 2024-12-18
AU2020203352A1 (en) 2020-07-02
EP3177307A1 (fr) 2017-06-14
EA035956B1 (ru) 2020-09-04
EP3177307B1 (fr) 2024-07-17
CN107074967A (zh) 2017-08-18
LT3177307T (lt) 2024-08-12
MA40094B1 (fr) 2022-05-31
JP2021000084A (ja) 2021-01-07
ZA201700245B (en) 2024-06-26
AU2015301071A1 (en) 2017-02-02
CN107074967B (zh) 2021-06-08
CN113912737A (zh) 2022-01-11
CA2957273A1 (fr) 2016-02-11
CA2957273C (fr) 2023-03-14
EA202091342A2 (ru) 2020-11-30
MX2017001062A (es) 2017-07-14
AU2015301071B2 (en) 2020-03-05
MX388977B (es) 2025-03-20
PH12017500042A1 (en) 2017-05-22
CL2017000284A1 (es) 2017-11-17
MY180831A (en) 2020-12-10
US20170233448A1 (en) 2017-08-17
DK3177307T3 (da) 2024-10-07
US20250163118A1 (en) 2025-05-22
EP4438621A2 (fr) 2024-10-02
NZ766851A (en) 2024-07-26
SG11201700706WA (en) 2017-02-27
SA517380842B1 (ar) 2021-12-26
AU2020203352B2 (en) 2022-03-10
SMT202400414T1 (it) 2024-11-15
AU2015301071C1 (en) 2020-07-02
ES2986097T3 (es) 2024-11-08
EA202091342A3 (ru) 2020-12-30
IL275944B (en) 2022-02-01
IL275944A (en) 2020-08-31
KR20170030646A (ko) 2017-03-17
TN2017000020A1 (en) 2018-07-04
PT3177307T (pt) 2024-09-13
JP2017523789A (ja) 2017-08-24
SG10201913695PA (en) 2020-03-30
JP7272663B2 (ja) 2023-05-12
NZ728042A (en) 2024-07-26
US12084483B2 (en) 2024-09-10
IL250007A0 (en) 2017-03-30
PE20170503A1 (es) 2017-05-11
AU2022204034A1 (en) 2022-07-14
FI3177307T3 (fi) 2024-10-04
IL250007B (en) 2020-07-30
JP6723982B2 (ja) 2020-07-15
RS65930B1 (sr) 2024-10-31
KR102653758B1 (ko) 2024-04-04
US20230079120A1 (en) 2023-03-16
MA40721B1 (fr) 2024-08-30
BR112017001940A2 (pt) 2017-11-28
HUE068478T2 (hu) 2025-01-28
MA40094A1 (fr) 2021-09-30
WO2016022671A1 (fr) 2016-02-11
SI3177307T1 (sl) 2024-09-30

Similar Documents

Publication Publication Date Title
MA40721A (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3455263A4 (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
CL2016001868A1 (es) Proteinas de union y sus métodos de uso
EP3544629A4 (fr) Protéines trispécifiques ciblang le psma et procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
HRP20190028T1 (hr) Interleukin-2 fuzijski proteini i njihove primjene
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
EP3119761C0 (fr) Agents ciblant les amyloïdes et procédés de leur utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA42979A (fr) Anticorps anti-age et procédés d'utilisation correspondants
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation
EP3478277A4 (fr) Compositions anti-acné et procédés d'utilisation
EP3365016A4 (fr) Récepteurs de cellules universels programmables et leurs procédés d'utilisation
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
EP3212290A4 (fr) Polypeptides de fusion de serpine et leurs procédés d'utilisation
MA45326A (fr) Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
EP2994150A4 (fr) Probiotiques et procédés d'utilisation
DK3158058T3 (da) Fusionsproteiner og bruger deraf
EP3322736A4 (fr) Polypeptides de fusion et leurs procédés d'utilisation
EP3630794A4 (fr) Malacidines et procédés d'utilisation
EP3526580A4 (fr) Viscosimètre et procédés d'utilisation de ce dernier